Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
89.4 CHF | +0.60% | +0.33% | +5.14% |
01:00pm | Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis | CI |
04-29 | Novartis target Morphosys multiplies losses - takeover schedule stands | DP |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.14% | 199B | |
+36.09% | 664B | |
+28.99% | 567B | |
-7.15% | 354B | |
+19.35% | 330B | |
+4.22% | 286B | |
+13.51% | 234B | |
-10.06% | 196B | |
-4.82% | 148B | |
-10.92% | 145B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis Says Initial Data from Phase 3 Trial Show No Difference Between Crizanlizumab, Placebo